![Gary Abromovitz](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Historique de carrière de Gary Abromovitz
Anciens postes connus de Gary Abromovitz
Sociétés | Poste | Début | Fin |
---|---|---|---|
HELEN OF TROY LIMITED | Directeur/Membre du Conseil | 01/01/1990 | 24/08/2022 |
Independent Dir/Board Member | 01/01/1990 | 24/08/2022 | |
Venturis Therapeutics, Inc.
![]() Venturis Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Venturis Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the developing protein drug candidates to address diseases such as diabetic wounds, severe coronary heart disease and peripheral artery disease. The company develops injectable and topical formulations of its active pharmacological ingredient to facilitate the growth of new blood vessels in the heart, tissues and organs. It focuses on developing protein drug candidates to be used in the treatment of cardiovascular disease. CardioVascular BioTherapeutics was founded by Daniel C. Montano, Thomas J. Stegmann and Grant Gordon in March 1998 and is headquartered in Dallas, TX. | Directeur/Membre du Conseil | 01/02/2005 | 10/08/2012 |
Independent Dir/Board Member | 01/02/2005 | 10/08/2012 |
Statistiques
Internationale
Etats-Unis | 3 |
Opérationnelle
Director/Board Member | 2 |
Independent Dir/Board Member | 2 |
Sectorielle
Consumer Durables | 2 |
Commercial Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
HELEN OF TROY LIMITED | Consumer Durables |
Entreprise privées | 1 |
---|---|
Venturis Therapeutics, Inc.
![]() Venturis Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Venturis Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the developing protein drug candidates to address diseases such as diabetic wounds, severe coronary heart disease and peripheral artery disease. The company develops injectable and topical formulations of its active pharmacological ingredient to facilitate the growth of new blood vessels in the heart, tissues and organs. It focuses on developing protein drug candidates to be used in the treatment of cardiovascular disease. CardioVascular BioTherapeutics was founded by Daniel C. Montano, Thomas J. Stegmann and Grant Gordon in March 1998 and is headquartered in Dallas, TX. | Commercial Services |
- Bourse
- Insiders
- Gary Abromovitz
- Expérience